Ilyang Pharmaceutical Co.,Ltd (KRX:007570)

KRX:007570 Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	9,761	4,295	3,414	7,174	9,288	41,341
Short-Term Investments	6,705	8,495	10,276	5,419	34,111	1.77
Trading Asset Securities	-	-	-	-	231.78	269.1
Cash & Short-Term Investments	16,466	12,790	13,690	12,593	43,631	41,612
Cash Growth	-38.71%	-6.57%	8.72%	-71.14%	4.85%	15.92%
Accounts Receivable	47,260	44,961	47,656	48,762	52,803	58,678
Other Receivables	5,382	3,936	4,680	4,716	3,297	6,241
Receivables	52,642	48,897	52,336	53,479	56,101	64,945
Inventory	73,670	59,873	53,108	48,387	32,423	48,590
Prepaid Expenses	341.11	158.02	186.42	303.23	515.3	640.96
Other Current Assets	4,035	3,652	4,339	3,656	3,671	6,707
Total Current Assets	147,154	125,370	123,659	118,418	136,340	162,496
Property, Plant & Equipment	213,058	216,421	181,973	178,244	175,779	185,966
Long-Term Investments	40,311	43,510	38,572	52,847	45,029	2,513
Other Intangible Assets	1,759	1,888	1,826	1,935	2,078	3,654
Long-Term Deferred Charges	23,785	23,453	25,530	29,481	34,392	55,747
Other Long-Term Assets	26,693	20,568	21,046	21,991	25,643	28,742
Total Assets	452,760	431,211	392,607	402,916	419,261	439,117
Accounts Payable	25,622	22,322	26,307	29,813	23,717	23,663
Accrued Expenses	450.95	513.8	398.44	310.58	314.19	173.36
Short-Term Debt	88,800	92,505	65,789	71,000	92,500	84,256
Current Portion of Long-Term Debt	2,500	-	-	2,000	-	18,485
Current Portion of Leases	341.38	266.59	522.11	370.52	159.24	-
Current Income Taxes Payable	1,698	1,293	1,126	958.54	3,542	3,976
Other Current Liabilities	40,506	40,002	45,121	40,875	47,687	46,594
Total Current Liabilities	159,918	156,902	139,263	145,328	167,920	177,147
Long-Term Debt	27,500	14,700	6,000	-	5,000	-
Long-Term Leases	334.95	209.38	339.24	732.69	843.73	300.62
Pension & Post-Retirement Benefits	8,834	8,580	7,322	7,909	8,136	8,785
Long-Term Deferred Tax Liabilities	8,320	8,934	9,233	10,662	10,464	7,962
Other Long-Term Liabilities	40	310	50	500	21.5	0
Total Liabilities	204,947	189,635	162,207	165,132	192,385	194,195
Common Stock	47,714	47,714	47,714	47,714	47,714	47,714
Additional Paid-In Capital	78,370	78,370	78,441	78,416	78,590	78,795
Retained Earnings	70,778	61,101	53,559	58,759	43,170	31,413
Treasury Stock	-12,269	-11,269	-11,921	-10,075	-7,437	-7,743
Comprehensive Income & Other	58,310	60,966	57,957	58,496	60,587	55,902
Total Common Equity	242,903	236,881	225,751	233,311	222,624	206,081
Minority Interest	3,798	3,582	3,536	3,361	3,139	37,728
Shareholders' Equity	247,813	241,576	230,400	237,785	226,876	244,922
Total Liabilities & Equity	452,760	431,211	392,607	402,916	419,261	439,117
Total Debt	119,476	107,681	72,650	74,103	98,503	103,041
Net Cash (Debt)	-103,011	-94,891	-58,960	-61,511	-54,872	-61,429
Net Cash Per Share	-5738.96	-5280.07	-3272.13	-3393.60	-3014.10	-3374.26
Filing Date Shares Outstanding	18.42	18.01	17.97	18.09	18.21	18.21
Total Common Shares Outstanding	18.42	18.01	17.97	18.09	18.21	18.21
Working Capital	-12,764	-31,532	-15,604	-26,910	-31,580	-14,651
Book Value Per Share	13185.35	13150.27	12561.42	12899.45	12228.63	11319.92
Tangible Book Value	241,143	234,994	223,925	231,375	220,547	202,427
Tangible Book Value Per Share	13089.85	13045.48	12459.79	12792.46	12114.49	11119.20
Land	115,120	120,507	120,298	120,308	116,955	102,083
Buildings	39,688	41,126	42,787	44,474	45,995	57,001
Machinery	3,270	4,055	6,060	9,367	9,480	14,843
Construction In Progress	54,380	49,583	11,435	2,384	1,953	11,144

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.